Resources
About Us
South East Asia IVD Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics, Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology, Diabetes), Diagnostic Approach (Lab, POC) - Forecast to 2030
Report ID: MRHC - 104930 Pages: 200 Jul-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 72 Hours Download Free Sample ReportThe South East Asia IVD Market is expected to record a CAGR of 7% from 2024 to 2030, reaching $4.11 billion by 2030. In vitro diagnostics (IVD) are tests performed on biological samples such as blood, saliva, and other tissues taken from the human body to detect a wide range of diseases. IVD tests screen biological samples to monitor individuals’ health and prevent or diagnose diseases. These consist of various tests based on techniques such as enzyme-linked immunosorbent assay (ELISA), radioimmunoassay, polymerase chain reaction (PCR), isothermal nucleic acid amplification, and next-generation sequencing. These tests can be performed in laboratories, homes, and healthcare facilities.
The growth of this market is driven by the high prevalence of infectious diseases and the rising risk of emerging infections, the high burden of chronic diseases, and the growing focus on strengthening the healthcare industry in the region. Additionally, growing awareness regarding early disease diagnosis and growing medical tourism in the region are expected to create growth opportunities for the stakeholders in this market. However, the large import of tests and instruments and limited local manufacturing facilities restrain the growth of this market. Poor healthcare access in remote populations is a major challenge to market growth.
Despite the progress in healthcare, the region bears a significant burden of infectious diseases. The region has one of the largest HIV and tuberculosis burdens globally. South East Asia also has the third highest incidence of Malaria in all the WHO regions. Such high burden and incidence of infectious diseases create a demand for fast and efficient testing driving the IVD market in the region.
The South East Asian region is considered a high-risk hotspots and home for emerging infectious diseases (EID). The outbreaks of various novel influenza strain spillage of the Nipah virus were seen in these countries. This can be attributed to the highly diverse wildlife and changing demographics that bring the human population closer to the forests and natural wildlife reservoirs. These wildlife reservoirs are home to several pathogens and viruses. These viruses and pathogens are very likely to spill over and infect humans. Therefore, to prevent the further spread of these infections, there arises a need for early, rapid, and precise testing, driving the market growth.
Following are some recent infectious disease outbreaks in the region:
Click here to: Get Free Sample Pages of this Report
Development of healthcare infrastructure leads to increased accessibility of healthcare institutions, disease diagnostics & management, and improved overall health system. Compared to other developed regions, the healthcare system is underdeveloped in South East Asia. Looking at the high burden of infectious and chronic diseases in the region, governments and international organizations are focusing on developing healthcare in the region. For instance, in 2021, the U.S. government provided USD 40 million to the Association of Southeast Nations to strengthen the region's research and health system capacity.
Moreover, in 2021, the World Health Organization launched the ‘South-East Asia Regional Strategy for Primary Health Care: 2022-2030’ initiative. This initiative aims to accelerate the progress of all the countries in the South East Asia region towards universal health coverage (UHC) and health security and health-related sustainable development goals. Such initiatives are expected to strengthen the healthcare systems of the countries in the region, leading to increasing demand for in vitro diagnostic testing and ultimately driving market growth.
The segment's growth can be attributed to the initiatives by the government, private players, and institutions to support the development of molecular diagnostics and constant innovation and advancements in molecular technologies.
The rising adoption of point-of-care tests, the rising prevalence of chronic & infectious diseases, and the increasing launches of new disease-specific kits are the key factors contributing to the growing demand for consumables. Furthermore, the COVID-19 pandemic significantly boosted the demand for IVD reagents, assays, and kits in the region. For instance, in June 2020, WHO, in collaboration with the Indonesian Ministry of Health to enhance COVID-19 case detection and help strengthen Indonesia’s laboratories, supported the procurement and distribution of COVID-19 test kits.
The factors propelling the segment's growth include the high burden and increasing prevalence of cardiac disorders in the region, growing research on the development of cardiac biomarkers, and initiatives taken by organizations to increase awareness regarding cardiac diseases. The rate of deaths due to non-communicable diseases in South East Asia is high. One of the major diseases includes cardiovascular disease. According to the World Heart Federation, cardiovascular diseases account for around one-third of the total deaths in South East Asia, accounting for 4 million deaths per year.
The increasing demand for rapid and accurate testing is due to the large number of deaths caused by non-communicable diseases, including cardiovascular diseases, cancer, and diabetes, among others. Furthermore, the initiatives for strengthening healthcare infrastructure in the regions drive segment growth.
The increasing demand for rapid and accurate testing is due to the large number of deaths caused by non-communicable diseases, including cardiovascular diseases, cancer, and diabetes, among others. Furthermore, the initiatives for strengthening healthcare infrastructure in the regions drive segment growth. The large share of the segment can be attributed to the majority and complex diagnostic tests carried out by diagnostic laboratories, the high burden of infectious and chronic diseases, and the associations of hospitals with diagnostic laboratories. Hospitals are people's primary choice if symptoms are onset for any disease or disorder. Most regional hospitals outsource the test samples to diagnostic laboratories for precise test results.
In 2024, Indonesia is expected to dominate the South East Asia IVD market. The factors attributed to the large share are the high prevalence of infectious diseases, the increasing prevalence of chronic diseases, and the growing awareness regarding early disease diagnosis. For instance, new caser cases are estimated to increase to 645,436 by 2040 from 396,914 cases in 2020 (Source: GLOBCAN).
Key Players
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presence, and key strategic developments adopted by leading market players in this market in the last three to four years. The key players profiled in the South East Asia IVD market are Abbott Laboratories (U.S.), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), and Sysmex Corporation. (U.S.).
Scope of the Report:
Key Questions Answered in the Report:
The South East Asia IVD market report covers market sizes & forecasts for reagents & kits, systems/instruments, and software & services. The South East Asia IVD market study includes the value analysis of various segments and subsegments of the South East Asia IVD market at the country level.
The South East Asia IVD market is projected to reach $4.11 billion by 2030, at a CAGR of 7% from 2024 to 2030.
The reagents & kits segment is estimated to account for the largest share of the South East Asia IVD market in 2024.
Based on technology, the molecular diagnostics segment is projected to gain more traction in the South East Asia IVD market.
Based on application, the cardiology segment is projected to gain more traction in the South East Asia IVD market.
The high growth of the South East Asia IVD market is mainly attributed to the high prevalence of infectious diseases and high risk of emerging infections, the high burden of chronic diseases, and the growing focus on strengthening the healthcare industry in the region. Additionally, growing awareness regarding early disease diagnosis and growing medical tourism in the region are expected to create growth opportunities for the stakeholders in this market.
The key players operating in the South East Asia IVD market are Abbott Laboratories (U.S.), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), and Sysmex Corporation (U.S.).
Indonesia is expected to offer significant growth opportunities for the vendors in this market due to the high prevalence of infectious diseases, the increasing prevalence of chronic diseases, and the growing awareness regarding early disease diagnosis.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for this Study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. High Prevalence of Infectious Diseases and High Risk of Emerging Infections
4.2.2. High Burden of Chronic Diseases
4.2.3. Growing Focus to Strengthen Healthcare Industry in The Region
4.3. Restraints
4.3.1. The Large Import of Tests and Instruments and Limited Local Manufacturing Facilities
4.4. Opportunity
4.4.1. Growing Awareness Regarding Early Disease Diagnosis
4.4.2. Growing Medical Tourism
4.5. Challenges
4.5.1. Poor healthcare access in remote populations
4.6. Trends
4.7. Pricing Analysis
4.8. Regulatory Analysis
4.9. Porters Five Force Analysis
4.9.1. Bargaining Power of Buyers
4.9.2. Bargaining Power of Suppliers
4.9.3. Threat of Substitute
4.9.4. Threat of New Entrant
4.9.5. Degree of Competition
5. South East Asia In Vitro Diagnostics Market Assessment — by Offering
5.1. Overview
5.2. Reagents & Kits
5.3. Instruments
5.4. Software & Services
6. South East Asia In Vitro Diagnostics Market Assessment—by Technology
6.1. Overview
6.2. Molecular Diagnostics
6.3. Point of Care (PoC) Diagnostics
6.3.1. Lateral Flow Assays/Rapid Tests
6.3.2. Other POC
6.4. Immunoassay/Immunochemistry
6.4.1. Enzyme-linked Immunosorbent Assays (ELISA)
6.4.2. Enzyme-linked Immunospot Assays (ELISPOT)
6.4.3. Western Blotting
6.4.4. Radioimmunoassay
6.5. Biochemistry/Clinical Chemistry
6.5.1. Metabolic Panels
6.5.2. Electrolyte Panels
6.5.3. Liver Panels
6.5.4. Lipid Profiles
6.5.5. Renal Profiles
6.5.6. Thyroid Function Panels
6.6. Whole Blood Glucose Monitoring
6.7. Hematology
6.8. Microbiology
6.9. Coagulation & Hemostasis
6.10. Urinalysis
6.11. Other IVD Technologies
7. South East Asia In Vitro Diagnostics Market Assessment — by Application
7.1. Overview
7.2. Infectious Diseases
7.3. Oncology
7.4. Cardiology
7.5. Diabetes
7.6. Autoimmune Disorders
7.7. Nephrology
7.8. Other Applications
8. South East Asia In Vitro Diagnostics Market Assessment — by Diagnostic Approach
8.1. Overview
8.2. Lab Testing
8.3. OTC/Self-testing
8.4. Point-of-care Testing
9. South East Asia In Vitro Diagnostics Market Assessment — by End User
9.1. Overview
9.2. Hospitals & Clinics
9.3. Diagnostic Laboratories
9.4. Home Healthcare
9.5. Other End Users
10. South East Asia In Vitro Diagnostics Market Assessment — by Country
10.1. Overview
10.2. Indonesia
10.3. Vietnam
10.4. Thailand
10.5. Malaysia
10.6. Singapore
10.7. Philippines
10.8. Rest of South East Asia
11. Competition Analysis
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Market Differentiators
11.4.3. Vanguards
11.4.4. Emerging Companies
11.5. Market Share Analysis/Market Ranking (2022)
12. Company Profiles (Company Overview, Financial Overview, Product Portfolio, Strategic Developments, *SWOT Analysis)
12.1. Abbott Laboratories
12.2. Bio-Rad Laboratories, Inc.
12.3. bioMérieux SA
12.4. Danaher Corporation
12.5. F. Hoffmann-La Roche Ltd.
12.6. QIAGEN N.V.
12.7. Siemens Healthineers AG (A Subsidiary of Siemens AG)
12.8. Thermo Fisher Scientific, Inc.
12.9. Sysmex Corporation
12.10. PerkinElmer, Inc.
(Note: SWOT Analysis of the top 5 companies operating in the market will be provided.)
13 Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 South East Asia In Vitro Diagnostics (IVD) Market, by Offering, 2021–2030 (USD Million)
Table 2 South East Asia IVD Reagents & Kits Market, by Country/Region, 2021–2030 (USD Million)
Table 3 South East Asia IVD Systems/Instruments Market, by Country/Region, 2021–2030 (USD Million)
Table 4 South East Asia IVD Software & Services Market, by Country/Region, 2021–2030 (USD Million)
Table 5 South East Asia In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 6 South East Asia Molecular Diagnostics Market, by Country/Region, 2021–2030 (USD Million)
Table 7 South East Asia Point-of-care (PoC) Diagnostics Market, by Country/Region, 2021–2030 (USD Million)
Table 8 South East Asia Point-of-care (PoC) Diagnostics Market, by type, 2021–2030 (USD Million)
Table 9 South East Asia Point-of-care (PoC) Diagnostics Market for Lateral Flow Assays/Rapid Tests, by Country/Region, 2021–2030 (USD Million)
Table 10 South East Asia Point-of-care (PoC) Diagnostics Market for Other PoC, by Country/Region, 2021–2030 (USD Million)
Table 11 South East Asia Immunoassay/Immunochemistry Market, by type, 2021–2030 (USD Million)
Table 12 South East Asia Immunoassay/Immunochemistry Market, by Country/Region, 2021–2030 (USD Million)
Table 13 South East Asia Enzyme-linked Immunosorbent Assays (ELISA) Market, by Country/Region, 2021–2030 (USD Million)
Table 14 South East Asia Enzyme-linked Immunospot Assays (ELISPOT) Market, by Country/Region, 2021–2030 (USD Million)
Table 15 South East Asia Western Blotting Market, by Country/Region, 2021–2030 (USD Million)
Table 16 South East Asia Radioimmunoassay Market, by Country/Region, 2021–2030 (USD Million)
Table 17 South East Asia Biochemistry/Clinical Chemistry Market, by type, 2021–2030 (USD Million)
Table 18 South East Asia Biochemistry/Clinical Chemistry Market, by Country/Region, 2021–2030 (USD Million)
Table 19 South East Asia Metabolic Market, by Country/Region, 2021–2030 (USD Million)
Table 20 South East Asia Electrolyte Panels Market, by Country/Region, 2021–2030 (USD Million)
Table 21 South East Asia Liver Panels Market, by Country/Region, 2021–2030 (USD Million)
Table 22 South East Asia Lipid Profiles Market, by Country/Region, 2021–2030 (USD Million)
Table 23 South East Asia Renal Profiles Market, by Country/Region, 2021–2030 (USD Million)
Table 24 South East Asia Thyroid Functional Panels Market, by Country/Region, 2021–2030 (USD Million)
Table 25 South East Asia Whole Blood Glucose Monitoring Market, by Country/Region, 2021–2030 (USD Million)
Table 26 South East Asia Hematology Market, by Country/Region, 2021–2030 (USD Million)
Table 27 South East Asia IVD Market for Microbiology, by Country/Region, 2021–2030 (USD Million)
Table 28 South East Asia Coagulation and Hemostasis Market, by Country/Region, 2021–2030 (USD Million)
Table 29 South East Asia Urinalysis Market, by Country/Region, 2021–2030 (USD Million)
Table 30 South East Asia Other IVD Technologies Market, by Country/Region, 2021–2030 (USD Million)
Table 31 South East Asia In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 32 South East Asia In Vitro Diagnostics Market for Infectious Diseases, by Type, 2024–2030 (USD Million)
Table 33 South East Asia In Vitro Diagnostics Market for Infectious Diseases, by Country/Region, 2024–2030 (USD Million)
Table 34 South East Asia In Vitro Diagnostics Market for Influenza, by Country/Region, 2024–2030 (USD Million)
Table 35 South East Asia In Vitro Diagnostics Market for COVID-19, by Country/Region, 2024–2030 (USD Million)
Table 36 South East Asia In Vitro Diagnostics Market for Gastrointestinal Infections, by Country/Region, 2024–2030 (USD Million)
Table 37 South East Asia In Vitro Diagnostics Market for Oncology, by Country/Region, 2024–2030 (USD Million)
Table 38 South East Asia In Vitro Diagnostics Market for Cardiology, by Country/Region, 2024–2030 (USD Million)
Table 39 South East Asia In Vitro Diagnostics Market for Diabetes, by Country/Region, 2024–2030 (USD Million)
Table 40 South East Asia In Vitro Diagnostics Market for Autoimmune Disorders, by Country/Region, 2024–2030 (USD Million)
Table 41 South East Asia In Vitro Diagnostics Market for Nephrology, by Country/Region, 2024–2030 (USD Million)
Table 42 South East Asia In Vitro Diagnostics Market for Other Applications, by Country/Region, 2024–2030 (USD Million)
Table 43 South East Asia In Vitro Diagnostics Market, by Diagnostic Approach, 2021–2030 (USD Million)
Table 44 South East Asia In Vitro Diagnostics Market for Lab Testing, by Country/Region, 2024–2030 (USD Million)
Table 45 South East Asia In Vitro Diagnostics Market for OTC/Self-testing, by Country/Region, 2024–2030 (USD Million)
Table 46 South East Asia In Vitro Diagnostics Market for Point-of-care Testing, by Country/Region, 2024–2030 (USD Million)
Table 47 South East Asia In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 48 South East Asia In Vitro Diagnostics Market for Hospitals & Clinics, by Country/Region, 2021–2030 (USD Million)
Table 49 South East Asia In Vitro Diagnostics Market for Diagnostic Laboratories, by Country/Region, 2021-2030 (USD Million)
Table 50 South East Asia In Vitro Diagnostics Market for Home Healthcare, by Country/Region, 2021-2030 (USD Million)
Table 51 South East Asia In Vitro Diagnostics Market for Other End Users, by Country/Region, 2021-2030 (USD Million)
Table 52 South East Asia In Vitro Diagnostic Market, by Country/Region, 2021–2030 (USD Million)
Table 53 South East Asia: In Vitro Diagnostics Market, by Offering, (2021–2030) (USD Million)
Table 54 South East Asia: In Vitro Diagnostics Market, by Technology, (2021–2030) (USD Million)
Table 55 South East Asia: In Vitro Diagnostics Market, by Application, (2021–2030) (USD Million)
Table 56 South East Asia: In Vitro Diagnostics Market, by Diagnostic Approach, (2021–2030) (USD Million)
Table 57 South East Asia: In Vitro Diagnostics Market, by End User, (2021–2030) (USD Million)
Table 58 Indonesia: In Vitro Diagnostics Market, by Offering, (2021–2030) (USD Million)
Table 59 Indonesia: In Vitro Diagnostics Market, by Technology, (2021–2030) (USD Million)
Table 60 Indonesia: Point-of-care (PoC) Diagnostics Market, by type, 2021–2030 (USD Million)
Table 61 Indonesia: Immunoassay/Immunochemistry Market, by type, 2021–2030 (USD Million)
Table 62 Indonesia: Biochemistry/Clinical Chemistry Market, by type, 2021–2030 (USD Million)
Table 63 Indonesia: In Vitro Diagnostics Market, by Application, (2021–2030) (USD Million)
Table 64 Indonesia: In Vitro Diagnostics Market for Infectious Diseases, by type, 2024–2030 (USD Million)
Table 65 Indonesia: In Vitro Diagnostics Market, by Diagnostic Approach, (2021–2030) (USD Million)
Table 66 Indonesia: In Vitro Diagnostics Market, by End User, (2021–2030) (USD Million)
Table 67 Vietnam: In Vitro Diagnostics Market, by Offering, (2021–2030) (USD Million)
Table 68 Vietnam: In Vitro Diagnostics Market, by Technology, (2021–2030) (USD Million)
Table 69 Vietnam: Point-of-care (PoC) Diagnostics Market, by type, 2021–2030 (USD Million)
Table 70 Vietnam: Immunoassay/Immunochemistry Market, by type, 2021–2030 (USD Million)
Table 71 Vietnam: Biochemistry/Clinical Chemistry Market, by type, 2021–2030 (USD Million)
Table 72 Vietnam: In Vitro Diagnostics Market, by Application, (2021–2030) (USD Million)
Table 73 Vietnam: In Vitro Diagnostics Market for Infectious Diseases, by type, 2024–2030 (USD Million)
Table 74 Vietnam: In Vitro Diagnostics Market, by Diagnostic Approach, (2021–2030) (USD Million)
Table 75 Vietnam: In Vitro Diagnostics Market, by End User, (2021–2030) (USD Million)
Table 76 Thailand: In Vitro Diagnostics Market, by Offering, (2021–2030) (USD Million)
Table 77 Thailand: In Vitro Diagnostics Market, by Technology, (2021–2030) (USD Million)
Table 78 Thailand: Point-of-care (PoC) Diagnostics Market, by type, 2021–2030 (USD Million)
Table 79 Thailand: Immunoassay/Immunochemistry Market, by type, 2021–2030 (USD Million)
Table 80 Thailand: Biochemistry/Clinical Chemistry Market, by type, 2021–2030 (USD Million)
Table 81 Thailand: In Vitro Diagnostics Market, by Application, (2021–2030) (USD Million)
Table 82 Thailand: In Vitro Diagnostics Market for Infectious Diseases, by type, 2024–2030 (USD Million)
Table 83 Thailand: In Vitro Diagnostics Market, by Diagnostic Approach, (2021–2030) (USD Million)
Table 84 Thailand: In Vitro Diagnostics Market, by End User, (2021–2030) (USD Million)
Table 85 Malaysia: In Vitro Diagnostics Market, by Offering, (2021–2030) (USD Million)
Table 86 Malaysia: In Vitro Diagnostics Market, by Technology, (2021–2030) (USD Million)
Table 87 Malaysia: Point-of-care (PoC) Diagnostics Market, by type, 2021–2030 (USD Million)
Table 88 Malaysia: Immunoassay/Immunochemistry Market, by type, 2021–2030 (USD Million)
Table 89 Malaysia: Biochemistry/Clinical Chemistry Market, by type, 2021–2030 (USD Million)
Table 90 Malaysia: In Vitro Diagnostics Market, by Application, (2021–2030) (USD Million)
Table 91 Malaysia: In Vitro Diagnostics Market for Infectious Diseases, by type, 2024–2030 (USD Million)
Table 92 Malaysia: In Vitro Diagnostics Market, by Diagnostic Approach, (2021–2030) (USD Million)
Table 93 Malaysia: In Vitro Diagnostics Market, by End User, (2021–2030) (USD Million)
Table 94 Singapore: In Vitro Diagnostics Market, by Offering, (2021–2030) (USD Million)
Table 95 Singapore: In Vitro Diagnostics Market, by Technology, (2021–2030) (USD Million)
Table 96 Singapore: Point-of-care (PoC) Diagnostics Market, by type, 2021–2030 (USD Million)
Table 97 Singapore: Immunoassay/Immunochemistry Market, by type, 2021–2030 (USD Million)
Table 98 Singapore: Biochemistry/Clinical Chemistry Market, by type, 2021–2030 (USD Million)
Table 99 Singapore: In Vitro Diagnostics Market, by Application, (2021–2030) (USD Million)
Table 100 Singapore: In Vitro Diagnostics Market for Infectious Diseases, by type, 2024–2030 (USD Million)
Table 101 Singapore: In Vitro Diagnostics Market, by Diagnostic Approach, (2021–2030) (USD Million)
Table 102 Singapore: In Vitro Diagnostics Market, by End User, (2021–2030) (USD Million)
Table 103 Philippines: In Vitro Diagnostics Market, by Offering, (2021–2030) (USD Million)
Table 104 Philippines: In Vitro Diagnostics Market, by Technology, (2021–2030) (USD Million)
Table 105 Philippines: Point-of-care (PoC) Diagnostics Market, by type, 2021–2030 (USD Million)
Table 106 Philippines: Immunoassay/Immunochemistry Market, by type, 2021–2030 (USD Million)
Table 107 Philippines: Biochemistry/Clinical Chemistry Market, by type, 2021–2030 (USD Million)
Table 108 Philippines: In Vitro Diagnostics Market, by Application, (2021–2030) (USD Million)
Table 109 Philippines: In Vitro Diagnostics Market for Infectious Diseases, by type, 2024–2030 (USD Million)
Table 110 Philippines: In Vitro Diagnostics Market, by Diagnostic Approach, (2021–2030) (USD Million)
Table 111 Philippines: In Vitro Diagnostics Market, by End User, (2021–2030) (USD Million)
Table 112 Rest of South East Asia: In Vitro Diagnostics Market, by Offering, (2021–2030) (USD Million)
Table 113 Rest of South East Asia: In Vitro Diagnostics Market, by Technology, (2021–2030) (USD Million)
Table 114 Rest of South East Asia: Point-of-care (PoC) Diagnostics Market, by type, 2021–2030 (USD Million)
Table 115 Rest of South East Asia: Immunoassay/Immunochemistry Market, by type, 2021–2030 (USD Million)
Table 116 Rest of South East Asia: Biochemistry/Clinical Chemistry Market, by type, 2021–2030 (USD Million)
Table 117 Rest of South East Asia: In Vitro Diagnostics Market, by Application, (2021–2030) (USD Million)
Table 118 Rest of South East Asia: In Vitro Diagnostics Market for Infectious Diseases, by type, 2024–2030 (USD Million)
Table 119 Rest of South East Asia: In Vitro Diagnostics Market, by Diagnostic Approach, (2021–2030) (USD Million)
Table 120 Rest of South East Asia: In Vitro Diagnostics Market, by End User, (2021–2030) (USD Million)
Table 121 Recent Developments, by Company, 2020–2024
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for this Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 South East Asia In Vitro Diagnostics Market, by Offering, 2024 Vs 2030 (USD Million)
Figure 8 South East Asia In Vitro Diagnostics Market, by Technology, 2024 Vs 2030 (USD Million)
Figure 9 South East Asia In Vitro Diagnostics Market, by Application, 2024 Vs 2030 (USD Million)
Figure 10 South East Asia In Vitro Diagnostics Market, by End User, 2024 Vs 2030 (USD Million)
Figure 11 South East Asia In Vitro Diagnostics Market, by Country/Region
Figure 12 Market Dynamics
Figure 13 South East Asia In Vitro Diagnostics (IVD) Market, by Offering, 2024–2030 (USD Million)
Figure 14 South East Asia In Vitro Diagnostics Market, by Technology, 2024 Vs 2030 (USD Million)
Figure 15 South East Asia In Vitro Diagnostics Market, by Application, 2024–2030 (USD Million)
Figure 16 South East Asia In Vitro Diagnostics Market, by Diagnostic Approach, 2024–2030 (USD Million)
Figure 17 South East Asia In Vitro Diagnostics Market, by End User, 2024 Vs. 2030 (USD Million)
Figure 18 South East Asia In Vitro Diagnostics Market: Snapshot
Figure 19 Key Growth Strategies Adopted by Leading Players, 2020–2024
Figure 20 South East Asia In Vitro Diagnostics Market: Competitive Benchmarking
Figure 21 Market Share Analysis: South East Asia In Vitro Diagnostics Industry, 2022
Figure 22 Abbott Laboratories: Financial Overview (2022)
Figure 23 Bio-Rad Laboratories, Inc.: Financial Overview (2022)
Figure 24 bioMérieux SA: Financial Overview (2022)
Figure 25 Danaher Corporation: Financial Overview (2022)
Figure 26 F. Hoffmann-La Roche Ltd.: Financial Overview (2022)
Figure 27 QIAGEN N.V.: Financial Overview
Figure 28 Siemens Healthineers AG: Financial Overview (2022)
Figure 29 Thermo Fisher Scientific, Inc.: Financial Overview (2022)
Figure 30 Sysmex Corporation: Financial Overview (2022)
Figure 31 PerkinElmer, Inc.: Financial Overview (2022)
Published Date: Jul-2024
Published Date: Jul-2024
Published Date: Mar-2024
Please enter your corporate email id here to view sample report.
Subscribe to get the latest industry updates